At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
AK104biological
Likely dose
AK104 6mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label,Phase 1b/2 Study for Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating AK104 for Advanced Solid Tumors and Melanoma. Completed, enrolled 68 participants across 1 site.
Detailed Summary
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Melanoma
CountriesChina
CollaboratorsAkeso Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartDec 2019
Primary CompletionJun 2021
Study CompletionSep 2022
TodayJul 2026
First PostedNov 21, 2019
Enrollment StartDec 20, 2019
Primary CompletionJun 17, 2021
Study CompletionSep 23, 2022
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 6.6 years ago
Interventions
AK104biological
AK104, 6mg/kg, Q2W